NCCN Guidelines                         ®                          Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines

Al B. Benson; Alan P. Venook; Mahmoud M. Al-Hawary; Lynette Cederquist; Yi Jen Chen; Kristen K. Ciombor; Stacey Cohen; Harry S. Cooper; Dustin Deming; Paul F. Engstrom; Ignacio Garrido-Laguna; Jean L. Grem; Axel Grothey; Howard S. Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A. Messersmith; Jeffrey Meyerhardt; Eric D. Miller; Mary F. Mulcahy; James D. Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M. Skibber; Constantinos T. Sofocleous; Elena M. Stoffel; Eden Stotsky-Himelfarb; Christopher G. Willett; Evan Wuthrick; Kristina M. Gregory; Deborah A. Freedman-Cass

doi:10.6004/jnccn.2018.0021

NCCN Guidelines ^® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines

Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. MessersmithJeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Deborah A. Freedman-Cass

Research output: Contribution to journal › Comment/debate

584 Scopus citations

Abstract

The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.

Original language	English
Pages (from-to)	359-369
Number of pages	11
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	16
Issue number	4
DOIs	https://doi.org/10.6004/jnccn.2018.0021
State	Published - Apr 1 2018

Access to Document

10.6004/jnccn.2018.0021

Cite this

Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y. J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., Garrido-Laguna, I., Grem, J. L., Grothey, A., Hochster, H. S., Hoffe, S., Hunt, S., Kamel, A., Kirilcuk, N., Krishnamurthi, S., ... Freedman-Cass, D. A. (2018). NCCN Guidelines ^® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines JNCCN Journal of the National Comprehensive Cancer Network, 16(4), 359-369. https://doi.org/10.6004/jnccn.2018.0021

@article{2dfa8afb74bd49cd96313565526cb4b5,

title = " NCCN Guidelines {\textregistered} Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines ",

abstract = "The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.",

author = "Benson, {Al B.} and Venook, {Alan P.} and Al-Hawary, {Mahmoud M.} and Lynette Cederquist and Chen, {Yi Jen} and Ciombor, {Kristen K.} and Stacey Cohen and Cooper, {Harry S.} and Dustin Deming and Engstrom, {Paul F.} and Ignacio Garrido-Laguna and Grem, {Jean L.} and Axel Grothey and Hochster, {Howard S.} and Sarah Hoffe and Steven Hunt and Ahmed Kamel and Natalie Kirilcuk and Smitha Krishnamurthi and Messersmith, {Wells A.} and Jeffrey Meyerhardt and Miller, {Eric D.} and Mulcahy, {Mary F.} and Murphy, {James D.} and Steven Nurkin and Leonard Saltz and Sunil Sharma and David Shibata and Skibber, {John M.} and Sofocleous, {Constantinos T.} and Stoffel, {Elena M.} and Eden Stotsky-Himelfarb and Willett, {Christopher G.} and Evan Wuthrick and Gregory, {Kristina M.} and Freedman-Cass, {Deborah A.}",

note = "Funding Information: This activity is supported by educational grants from AstraZeneca, Celldex Therapeutics, Celgene Corporation, Genentech, Jazz Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc. This activity is supported by independent educational grants from AbbVie, Merck & Co., Inc. and NOVOCURE. Publisher Copyright: {\textcopyright}{\textcopyright} JNCCN-Journal JNCCN-Journal of of the the National National Comprehensive Comprehensive Cancer Cancer Network Network",

year = "2018",

month = apr,

day = "1",

doi = "10.6004/jnccn.2018.0021",

language = "English",

volume = "16",

pages = "359--369",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "4",

}

Benson, AB, Venook, AP, Al-Hawary, MM, Cederquist, L, Chen, YJ, Ciombor, KK, Cohen, S, Cooper, HS, Deming, D, Engstrom, PF, Garrido-Laguna, I, Grem, JL, Grothey, A, Hochster, HS, Hoffe, S, Hunt, S, Kamel, A, Kirilcuk, N, Krishnamurthi, S, Messersmith, WA, Meyerhardt, J, Miller, ED, Mulcahy, MF, Murphy, JD, Nurkin, S, Saltz, L, Sharma, S, Shibata, D, Skibber, JM, Sofocleous, CT, Stoffel, EM, Stotsky-Himelfarb, E, Willett, CG, Wuthrick, E, Gregory, KM & Freedman-Cass, DA 2018, ' NCCN Guidelines ^® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines ', JNCCN Journal of the National Comprehensive Cancer Network, vol. 16, no. 4, pp. 359-369. https://doi.org/10.6004/jnccn.2018.0021

NCCN Guidelines ^® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines . / Benson, Al B.; Venook, Alan P.; Al-Hawary, Mahmoud M. et al.
In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 16, No. 4, 01.04.2018, p. 359-369.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - NCCN Guidelines ® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines

AU - Benson, Al B.

AU - Venook, Alan P.

AU - Al-Hawary, Mahmoud M.

AU - Cederquist, Lynette

AU - Chen, Yi Jen

AU - Ciombor, Kristen K.

AU - Cohen, Stacey

AU - Cooper, Harry S.

AU - Deming, Dustin

AU - Engstrom, Paul F.

AU - Garrido-Laguna, Ignacio

AU - Grem, Jean L.

AU - Grothey, Axel

AU - Hochster, Howard S.

AU - Hoffe, Sarah

AU - Hunt, Steven

AU - Kamel, Ahmed

AU - Kirilcuk, Natalie

AU - Krishnamurthi, Smitha

AU - Messersmith, Wells A.

AU - Meyerhardt, Jeffrey

AU - Miller, Eric D.

AU - Mulcahy, Mary F.

AU - Murphy, James D.

AU - Nurkin, Steven

AU - Saltz, Leonard

AU - Sharma, Sunil

AU - Shibata, David

AU - Skibber, John M.

AU - Sofocleous, Constantinos T.

AU - Stoffel, Elena M.

AU - Stotsky-Himelfarb, Eden

AU - Willett, Christopher G.

AU - Wuthrick, Evan

AU - Gregory, Kristina M.

AU - Freedman-Cass, Deborah A.

N1 - Funding Information: This activity is supported by educational grants from AstraZeneca, Celldex Therapeutics, Celgene Corporation, Genentech, Jazz Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc. This activity is supported by independent educational grants from AbbVie, Merck & Co., Inc. and NOVOCURE. Publisher Copyright: ©© JNCCN-Journal JNCCN-Journal of of the the National National Comprehensive Comprehensive Cancer Cancer Network Network

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.

AB - The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.

UR - http://www.scopus.com/inward/record.url?scp=85045662724&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2018.0021

DO - 10.6004/jnccn.2018.0021

M3 - Comment/debate

C2 - 29632055

AN - SCOPUS:85045662724

SN - 1540-1405

VL - 16

SP - 359

EP - 369

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 4

ER -

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK et al. NCCN Guidelines ^® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines JNCCN Journal of the National Comprehensive Cancer Network. 2018 Apr 1;16(4):359-369. doi: 10.6004/jnccn.2018.0021

NCCN Guidelines ^® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this